The UK Proposes Major Medical Device Reforms: What the Draft Medical Devices (Amendment) Regulations 2026 Mean for Industry

What's Changed?

In May 2026, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) published the draft Medical Devices (Amendment) Regulations 2026, marking one of the most significant proposed reforms to Great Britain's medical device regulatory framework since Brexit.

The draft regulations introduce updated pre-market requirements for medical devices and in vitro diagnostic (IVD) devices, with proposals designed to strengthen patient safety while improving access to innovative technologies. Alongside the draft legislation, the MHRA launched a stakeholder impact survey to gather feedback from industry before the regulations are finalised.

Among the proposed changes are new approaches to international regulatory reliance, updated classification requirements for certain devices, enhanced oversight of software and AI-enabled medical devices, and strengthened post-market surveillance measures. The reforms are expected to be adopted in late 2026, with implementation beginning in 2027.

Why This Change Matters

The proposed reforms represent a significant evolution of the UK's regulatory framework.

Rather than simply replacing existing requirements, the draft regulations aim to create a more modern, proportionate, and internationally aligned system that supports innovation while maintaining high standards of patient safety.

For manufacturers seeking access to the Great Britain market, these changes may influence regulatory planning, product classification, technical documentation, and market entry strategies.

Who Needs to Pay Attention?

This proposed regulatory change is particularly relevant for:

✔ Medical device manufacturers

✔ In vitro diagnostic (IVD) manufacturers

✔ Software as a Medical Device (SaMD) developers

✔ Regulatory affairs professionals

✔ UK Responsible Persons

✔ Companies planning to place medical devices on the Great Britain market

Organisations with products intended for the UK market should begin assessing how the proposed reforms could affect future regulatory obligations.

What Companies Should Do Next

1. Review the Proposed Requirements

Evaluate how the draft regulations may affect existing regulatory strategies, product classifications, and conformity assessment pathways.

2. Assess Product Portfolios

Manufacturers should identify products that could be affected by revised classification rules or additional pre-market requirements.

3. Strengthen Regulatory Planning

Although the regulations are still in draft form, early preparation will help organisations respond efficiently once the final framework is adopted.

4. Monitor Future MHRA Announcements

The current consultation and stakeholder engagement process may result in further refinements before the regulations are implemented.

ARQon Insight

The UK's proposed reforms demonstrate how modern medical device regulation is evolving beyond compliance alone.

Regulators are increasingly adopting risk-based, internationally connected frameworks that aim to balance patient safety with timely access to innovative technologies.

For healthcare companies, regulatory agility is becoming a competitive advantage. Organisations that monitor regulatory developments early and integrate them into strategic planning will be better positioned to navigate future market access requirements.

Global Regulatory Trend

The UK's proposed reforms reflect a broader international movement toward smarter and more harmonised medical device regulation.

Across North America, Europe, Asia-Pacific, and Latin America, regulators are strengthening post-market surveillance, refining risk classifications, exploring international reliance models, and adapting regulatory frameworks to address emerging technologies such as software and artificial intelligence.

These developments reinforce the growing importance of globally aligned regulatory strategies for companies operating across multiple jurisdictions.

Key Takeaway

The draft Medical Devices (Amendment) Regulations 2026 represent an important milestone in the UK's evolving regulatory framework.

Although the proposals are not yet in force, manufacturers should begin evaluating their potential impact, reviewing regulatory strategies, and preparing for a more modern and internationally connected medical device regulatory environment.

Early preparation will help organisations adapt efficiently as the UK's future regulatory framework takes shape.

How ARQon Can Support

ARQon supports healthcare and life sciences companies with:

• Regulatory intelligence and monitoring

• UK market access strategy

• Medical device regulatory consulting

• Regulatory change impact assessments

• Global compliance planning

• Cross-border market access support

Stay Ahead. Stay Compliant. Stay Informed.

With ARQon Regulatory Intelligence.